NEWS

  • July 10, 2018

    Aeromics Initiates Phase 1 Clinical Trial of CNS Edema Inhibitor AER-271 In Healthy Human Volunteers

    BRANFORD, Conn., July 9, 2018 /PRNewswire/ -- Aeromics, Inc. ("Aeromics" or "the Company"), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people af...

    Read More
  • May 17, 2018

    CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC Device

    TORONTO, Canada, May 17, 2018 – CellAegis Devices Inc. (“CellAegis” or the “Company”) a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective so...

    Read More
  • May 8, 2018

    CellAegis to complete enrollment in U.S. autoRIC trial by end of 2018

    In addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expec...

    Read More
  • April 23, 2018

    VGS Initiates U.S. Pivotal Trial to Evaluate the Use of Its VEST Technology for Bypass Surgery

    TEL AVIV, Israel, April 23, 2018 /PRNewswire/ -- Vascular Graft Solutions Ltd (VGS) announces on enrollment of the first 20 patients into the VEST US pivotal trial that will evaluate the safety and ef...

    Read More
  • April 16, 2018

    Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema

    Herantis Pharma PlcCompany release 16 Apr 2018 at 9:00 am Herantis Pharma Plc (“Herantis”) announced today positive results from a safety evaluation in the ongoing Phase 1 clinical study assessin...

    Read More
  • April 10, 2018

    CellAegis Announces First Patients Enrolled in U.S. Shield Pivotal Clinical Trial

    TORONTO, Canada, April 10, 2018 (GLOBE NEWSWIRE) – CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe a...

    Read More
  • March 20, 2018

    Broadview Ventures 2017 Annual Report

    Broadview Ventures 2017 Annual Report...

    Read More
  • March 12, 2018

    Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation

    COPENHAGEN, Denmark— 12 March 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac ...

    Read More
  • March 8, 2018

    Vectorious closes B round, setting stage for trials of heart-monitoring implant

    Vectorious Medical Technologies has raised cash to trial an implant for monitoring left atrial pressure in congestive heart failure patients, Globes reports. The series B round will fund a device the...

    Read More
  • February 8, 2018

    Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation

    COPENHAGEN, Denmark— 8 February 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhyt...

    Read More